Bird Flu Vaccine Developed Using AI Outperforms Current Stockpiled Vaccines in Preclinical Tests
Researchers used an AI-guided engineering approach to create a broadly protective bird flu vaccine that is designed to remain effective across a wide range of existing and future H5Nx variants. The post Bird Flu Vaccine Developed Using AI Outperforms Current Stockpiled Vaccines in Preclinical Tests appeared first on GEN - Genetic Engineering and Biotechnology News .
Researchers at the University of Cambridge and its spin-out DIOSynVax have developed an AI-guided broad-spectrum bird flu vaccine that outperforms current stockpiled vaccines in preclinical tests. The new digitally engineered multi-antigen mRNA vaccine, termed DVX-panH5Nx, provides complete protection against diverse H5Nx variants, surpassing existing vaccines that protect only around 50% of exposed animals.
Current pandemic preparedness relies on stockpiling vaccines against individual virus variants, but the Cambridge team's approach anticipates viral evolution to remain effective against a wide range of existing and future variants. The study, published in Cell Reports Medicine, highlights the potential of AI in vaccine development for broad protective population immunity against evolving biological threats.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
